Intermediate-risk childhood acute lymphoblastic leukemias: amsacrine + cytosine arabinoside versus intermediate-dose methotrexate for consolidation, and 6-mercaptopurine + methotrexate + vincristine versus monthly pulses for maintenance.

DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Primary tabs

Schaison, G. Leverger, G. Bancillon, A Marty, M Olive, D. Cornu, Guy [UCL] Bonnet, M et al.[show all]

Document type	Article de périodique (Journal article) – Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial
Publication date	1987
Journal information	"Haematology and blood transfusion" - Vol. 30, p. 461-5 (1987)
issn	0171-7111
Publication status	Publié
Affiliation	UCL
MESH Subject	6-Mercaptopurine - administration & dosage ; Amsacrine - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Child ; Clinical Trials as Topic ; Cytarabine - administration & dosage ; Drug Administration Schedule ; Humans ; Leukemia, Lymphoid - drug therapy ; Methotrexate - administration & dosage ; Random Allocation ; Risk ; Vincristine - administration & dosage
Links	http://www.ncbi.nlm.nih.gov/pubmed/3305213[PubMed] http://hdl.handle.net/2078.1/27230[Handle]

Bibliographic reference	Schaison, G. ; Leverger, G. ; Bancillon, A ; Marty, M ; Olive, D. ; et. al. Intermediate-risk childhood acute lymphoblastic leukemias: amsacrine + cytosine arabinoside versus intermediate-dose methotrexate for consolidation, and 6-mercaptopurine + methotrexate + vincristine versus monthly pulses for maintenance.. In: Haematology and blood transfusion, Vol. 30, p. 461-5 (1987)
Permanent URL	http://hdl.handle.net/2078.1/27230